Protocol For Genomically Profiling, Collecting, Archiving And Distributing Blood And Bone Marrow Specimens From Children And Young Adults With Hematologic Malignancy

Launched by DANA-FARBER CANCER INSTITUTE · Jul 9, 2021

Keywords

ClinConnect Summary

This clinical trial is focused on understanding the genetic factors behind certain blood cancers, such as leukemia, myelodysplastic syndromes (MDS), and myeloproliferative syndromes (MPS), in children and young adults. The researchers will collect and analyze blood and bone marrow samples to learn more about how these diseases develop and why some treatments work better for some patients than others. By studying the genes in these samples, they hope to uncover important information that can improve future treatments and help personalize care for each patient. Additionally, the samples will be stored for future research, which can further our understanding of these conditions.

To be eligible for this study, participants must be between birth and 29 years old and have a diagnosis of one of the mentioned blood cancers. This can include individuals who are newly diagnosed or those whose disease has come back after treatment. Participants will need to have sufficient samples available for testing, either from previous procedures or from blood draws planned for their clinical care. If you or someone you know fits these criteria, joining this study can provide valuable information for current and future treatments, while also contributing to the broader understanding of these diseases.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age: birth to \< 30 years of age
• * Diagnosis:
• • -- Patient with acute leukemia, chronic leukemia, MDS/AML, myelodysplastic syndrome or myeloproliferative syndromes. Disease can be newly diagnosed or relapsed/refractory.
• * Pathology Criteria:
• • -- Histologic confirmation of leukemia or myelodysplastic syndrome (MDS) or myeloproliferative syndrome (MPS) at the time of diagnosis or recurrence
• * Specimen Criteria:
• • Sufficient sample available for genomic profiling OR bone marrow aspirate/blood draw planned for clinical care which is anticipated to allow collection of minimum specimen for testing (See Section 6.1 for description of specimen requirements)
• Exclusion Criteria:
• • - Insufficient leukemia or MDS specimen available for profiling from diagnosis or recurrence (See Section 6.1); or bone marrow evaluations NOT planned for clinical care; or peripheral blast percentage \<20%, or clinical blood draw not planned